Formulary updates

June 2018

  • Desmopressin nasal spray 10micrograms/spray and 100micrograms/ml have been reclassified from a red drug (hospital only) to an amber drug (specialist input), for use in the treatment of diabetes insipidus
    • Desmopressin tablets 100microgram and desmopressin sublingual tablets 60microgram have been added into the formulary for consistency with the BNF recommended dose (see here).
  • Pentasa® prolonged-release granules 4g have been added into the formulary here, to offer another strength options of the current preparation.
  • Salofalk® gastro-resistant prolonged-released granules 500mg, 1g, 1.5g, and 3g have been added to the formulary here, to provide another option for the maintenance of remission in those patients who have a high risk of relapses/ adherence difficulties.
  • Nausea and vomiting in pregnancy and hyperemesis gravidarum: The formulary guidance has been amended to offer clarity on the use of ondansetron as a 3 rd line treatment option. A link to the UK teratology information website, Best Use of Medicines in Pregnancy (BUMPS) has been added as a helpful resource. The guidance can be found here.
  • Asthma – paediatric treatment: NICE NG80: Asthma: diagnosis, monitoring and chronic asthma management (November 2017), prompted a review of the current guidance, which is based on recommendations made by the British Throacic Society (BTS) and the Scottish Intercollegiate Guideline Network (SIGN). Formulary guidance continues to follow the recommendations made by BTS/SIGN, with minor changes to offer clarity to existing guidance. The guidance can be found here.
  • Commissioning Policy: The routine commissioning of lurasidone is not accepted in Devon for patients with schizophrenia (see Commissioning Policy for more details)

Devon Formulary and Referral User Survey 2017

We would again like to thank everyone who took part in the Devon Formulary and Referral user survey last year. The responses have been analysed and the findings published:

April 2018

  • Eclypse® Border dressings have been added to the formulary here. They have a higher acquisition cost in comparison to the non-border dressing and should be reserved for use in patients with heavily exuding wounds and following specialist Tissue Viability Nurse assessment of the wound.
  • Prontosan® irrigation fluid and gel products have been removed from the formulary and replaced by Octenilin® irrigation solution and gel which can be found here. Octenilin® is indicated for wound cleansing, moisturising and decontamination, and has a quicker acting time than Prontosan®. Octenilin® products are indicated for short term use only and are unsuitable for repeat prescription.
  • Zeroveen® emollient cream has been added to the formulary here. It is an emollient 2-in-1 moisturising cream and wash containing oatmeal, similar in formulation to Aveeno® cream but available at a lower acquisition cost.
  • BD Microfine+ 0.20mm/33G lancets have been discontinued. AgaMatrix Ultra-Thin 0.20mm/33G lancets have been added to the formulary here for use with the Wavesense Jazz blood glucose monitoring meter.
  • Salofalk® 500mg and 1g suppositories, Salofalk® 2g liquid enema and Salofalk® 1g foam enema have been added to the formulary here. They have been added to the formulary for the management of ulcerative colitis; these products are classified as 'Specialist' drugs to reflect the need for specialist input but continuation supplies may be prescribed in primary care.
  • Linezolid tablets and granules for oral suspension have been added to the formulary here. Linezolid has been added as a red drug with supportive prescribing notes.
  • Following public consultation; NHS England (NHSE) and NHS Clinical Commissioners (NHSCC) published guidance for CCGs on items which should not be routinely prescribed in primary care. Click here for more information. The following items have new guidance attached in the formulary:
  • Management of Hypertension: The formulary guidance has been reviewed and minor amendments made in line with NICE clinical guideline 127 (CG127), November 2016. The guidance can be found here.

March 2018

  • FreeStyle Libre interstitial glucose monitor has been added into the formulary for patients with type 1 diabetes mellitus who meet specific initiation and continuation criteria, following a commissioning decision from the Clinical Policy Committee. This device should be initiated by specialist endocrinologists only. Please see the formulary for further information.

February 2018

  • Trimbow metered dose inhaler (MDI) (combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium) 87 micrograms/ 5 micrograms/ 9 micrograms has been added into the formulary, for use in patients aged 18 years and older with chronic obstructive pulmonary disease. Please see the formulary for further information.
  • Alprostadil intraurethral delivery systems 250 microgram, 500 microgram, and 1000 microgram have been added into the formulary, as an alternative treatment option to intracavernosal injection and topical aprostadil, for erectile dysfunction. Please see the formulary for further information.

 

Home > Formulary > Updates > Recent Updates

 

  • First line
  • Second line
  • Specialist
  • Hospital